17 February 2026 - Approval based on four Phase 3 trials with statistically significant and clinically meaningful primary data across severe asthma and chronic rhinosinusitis with nasal polyps.

GSK today announced the European Commission has approved Exdensur (depemokimab) in two indications:

• As add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids plus another asthma controller
• As an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Read GSK press release